Inhibitors of the Hippo Pathway Kinases STK3/MST2 and STK4/MST1 Have Utility for the Treatment of Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

Inhibitors of the Hippo Pathway Kinases STK3/MST2 and STK4/MST1 Have Utility for the Treatment of Acute Myeloid Leukemia

Published:2021-11-22 Issue:2 Volume:65 Page:1352-1369
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Bata Nicole¹,Chaikuad Apirat²³^ORCID,Bakas Nicole A.¹^ORCID,Limpert Allison S.¹,Lambert Lester J.¹^ORCID,Sheffler Douglas J.¹,Berger Lena M.²³^ORCID,Liu Guoxiong⁴,Yuan Cunxiang⁴,Wang Li⁴,Peng Yi⁴,Dong Jing⁴,Celeridad Maria¹,Layng Fabiana¹,Knapp Stefan²³⁵,Cosford Nicholas D. P.¹^ORCID

Affiliation:

1. Cell and Molecular Biology of Cancer Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, United States

2. Buchmann Institute for Molecular Life Sciences, Structural Genomics Consortium, Johann Wolfgang Goethe-University, D-60438 Frankfurt am Main, Germany

3. Institute for Pharmaceutical Chemistry, Max von Lauestrasse 9, Johann Wolfgang Goethe-University, D-60438 Frankfurt am Main, Germany

4. Chemistry Department, Viva Biotech Ltd., 581 Shen Kuo Road, Shanghai 201203, China

5. Translational cancer network DKTK site Frankfurt/Mainz and Frankfurt Cancer Institute (FCI), Johann Wolfgang Goethe-University, D-60438 Frankfurt am Main, Germany

Funder

National Cancer Institute

Pancreatic Cancer Action Network

Larry L. Hillblom Foundation

Structural Genomics Consortium

Epstein Family Foundation

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00804